BioStock Studio: Immunicum and DCprime enter immuno-oncology merger

Swedish Immunicum announced last week that it has entered into an agreement with Van Herk Investments to acquire all of the shares in DCprime, a Dutch clinical stage company developing cancer relapse vaccines aimed to reduce tumor recurrence. The goal of the merger is to establish global leadership in developing cell-based cancer immunotherapies. BioStock was able to link up with Immunicum’s CEO, Sven Rohmann, as well as DCprime’s CEO, Erik Manting, for virtual video interview to learn more about the big news.

Watch the full interview with Sven Rohmann and Erik Manting at biostock.se:

https://www.biostock.se/en/biostock-studio-immunicum-and-dcprime-enter-immuno-oncology-merger/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se